Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Van Rhee, Frits

PropertyValue
overview Dr. Frits van Rhee received his medical degree at Erasmus University, Rotterdam, Netherlands, and his PhD at the Imperial College of Science, Medicine and Technology, University of London. He trained in internal medicine and hematology in the UK, and in bone marrow transplantation (BMT) at Oxford and the Royal Postgraduate Medical School in London. Dr. van Rhee is a professor of medicine and director of developmental and translational medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. He also holds the Charles and Clydene Scharlau Chair for Hematological Malignancies Research. Dr. van Rhee holds memberships in the International Society for Experimental Hematology, the International Society for Cellular Therapy, and the European Group for Bone and Marrow Transplantation. He serves on the editorial review boards for Annals of Hematology, Bone Marrow Transplantation, and Cytotherapy. He has written hundreds of manuscripts and abstracts, as well as presented at scientific meetings. Dr. van Rhee's current research focuses on immunotherapy for myeloma. Dr. van Rhee is also a world-leading expert in Castleman's Disease.PublicationsMake an appointment with the UAMS Myeloma Institute

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Academic Article Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Academic Article Con: allogeneic transplantation in multiple myeloma.
Academic Article High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
Academic Article Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
Academic Article Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Academic Article Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
Academic Article Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
Academic Article Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs.
Academic Article Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Academic Article Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
Academic Article Allografting or autografting for myeloma.
Academic Article Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
Academic Article Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
Academic Article Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Academic Article Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
Academic Article The Arkansas approach to therapy of patients with multiple myeloma.
Academic Article Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Academic Article Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
Academic Article Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Academic Article Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
Academic Article Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
Academic Article First thalidomide clinical trial in multiple myeloma: a decade.
Academic Article Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
Academic Article Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
Academic Article International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Academic Article Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Academic Article F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
Concept Acute Disease
Concept Communicable Disease Control
Concept Bone Diseases
Concept Hematologic Diseases
Concept Disease Progression
Concept Graft vs Host Disease
Concept International Classification of Diseases
Concept Kidney Diseases
Concept Genetic Predisposition to Disease
Concept Disease Management
Concept Disease Models, Animal
Concept Asymptomatic Diseases
Concept Virus Diseases
Concept Disease-Free Survival
Concept Rare Diseases
Academic Article Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article CNTO 328, a Novel- Anti-Interleukin-6 Monoclonal Antibody, is an Active Treatment for Castleman Disease
Academic Article Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital
Academic Article Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction
Academic Article Hematology
Academic Article Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow
Academic Article HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Academic Article The future of autologous stem cell transplantation in myeloma.
Academic Article Siltuximab for multicentric Castleman disease.
Academic Article CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.
Academic Article Curing myeloma at last: defining criteria and providing the evidence.
Academic Article Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Academic Article Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions.
Academic Article Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Academic Article Idiopathic multicentric Castleman's disease: a systematic literature review.
Academic Article Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Academic Article Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.
Academic Article International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Academic Article Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article Treatment of Idiopathic Castleman Disease.
Academic Article Castleman Disease.
Academic Article The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.
Academic Article Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Academic Article International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Academic Article Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Grant Potentiating Natural Killer Cell Anti-Myeloma Effects
Grant UARK 2002-36, An Open Label, Phase I Extension Study to Assess the Long-Term Safety and Tolerability of MRA as a Treatment for Castleman’s Disease
Grant Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438
Academic Article Storming the Castle with TCP.
Academic Article Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.
Academic Article Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Academic Article An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
Academic Article Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Academic Article Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
Academic Article A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Grant Polymorphism in Castleman’s Disease
Academic Article Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
Academic Article Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Academic Article Accelerated single cell seeding in relapsed multiple myeloma.
Grant S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct...260489
Academic Article Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Academic Article Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Academic Article International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Academic Article ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
Academic Article The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma.
Academic Article Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Academic Article Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Academic Article Combinatorial treatment for unresectable unicentric Castleman disease.
Academic Article Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
Academic Article Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Academic Article Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Academic Article Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Academic Article Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Academic Article Idiopathic multicentric Castleman disease treated with siltuximab for 15?years: a case report.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article Nearly 70 years later: the continued unraveling of Castleman disease.
Academic Article The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Academic Article Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
Academic Article CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Grant Qualitative Research in Castleman's Disease: Exploring Patients' Perspectives through Interviews, Project #A2-7438
Academic Article Expression of integrin ?-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
Academic Article Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
Academic Article Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.
Academic Article CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
Academic Article Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
Academic Article EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
Academic Article Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
Academic Article Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Academic Article Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
Academic Article Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
Academic Article Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Grant ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease
Grant ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease
Academic Article Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.

Search Criteria
  • Disease